WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Also das klingt ja alles vielversprechend. Der Kurs spiegelt die positiven Ergebnisse ja noch nicht besonders wider.

https://www.prnewswire.com/news-releases/wuxi-biologics-congratulates-amicus-therapeutics-on-european-commission-approval-for-pombiliti-in-patients-with-late-onset-pompe-disease-301783244.html

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1261286/company-news/HK6

https://ir.amicusrx.com/node/22701/html ...On April 18, 2023, Amicus Therapeutics, Inc. (“Amicus”) entered into a Supply and Manufacturing Services Agreement (the “WuXi Agreement”) with WuXi Biologics (Hong Kong) Limited, WuXi Biologics Ireland Limited and WuXi Biologics Germany GmbH (collectively, “WuXi”). Pursuant to the terms of the WuXi Agreement, WuXi has agreed to manufacture and supply to Amicus, and Amicus has agreed to purchase from WuXi, both the active pharmaceutical ingredient (“API”) in ATB200 and the finished enzyme replacement drug product, consisting of the API formulated as a finished dosage form according to certain specifications (the “Drug Product”).  ... The WuXi Agreement has an initial term of five years from the effective date of the agreement, followed by successive two-year automatic renewal periods.  ...  

🎈

https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/with-wuxi-biologics-cayman-incs-hkg2269-price-down-59-this-w/amp

https://seekingalpha.com/article/4580154-after-2022-slowdown-wuxi-biologics-gets-growth-medicine-big-new-order After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order Summary • WuXi Biologics revenue growth slowed sharply to 48.4% last year, but it got a jumpstart with its signing of a major new order last month. • The company's major shareholder recently sold 56 million shares, the latest in a steady series of such sales since its listing in 2017. • Investors are likely drawn to the company’s steady growth, though it will need to show it can return to the high-growth fast lane after last year’s modest slowdown. ...

https://m.hk.investing.com/news/stock-market-news/article-296039

Big Bank Rating | Nomura: Maintain WuXi Biologics (2269 HK) Buy rating and target price cut to HK$94.91 https://finance.sina.cn/hkstock/sckxjfx/2023-02-14/detail-imyfrvfw9195388.d.html?from=wap

Zhongtai Securities: „Kauf“-Rating von WuXi Biologics (02269) beibehalten, Kommerzialisierungsprojekte dürften weiterhin an Volumen zunehmen https://m.hk.investing.com/news/stock-market-news/article-295664

Wuxi Biologics Slips on Lower-Than-Expected Guidance https://www.marketwatch.com/amp/story/wuxi-biologics-slips-on-lower-than-expected-guidance-3c76f7aa

POSITIVE PROFIT ALERT Download https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a230213.pdf

DATE OF BOARD MEETING Download https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a230213a.pdf

"Profit Forecast" WuXi Biologics (02269 HK) Estimates Annual Earnings 30% More, Revenue Increases 48% http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1244741/1